Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Pegylated Liposomal Doxorubicin: A Guide To Its Use In Various Malignancies

K. Lyseng-Williamson, S. Duggan, G. Keating
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Pegylated liposomal doxorubicin (Caelyx® [EU], Doxil® [USA]) represents an improved formulation of conventional doxorubicin, with reduced cardiotoxicity and an improved pharmacokinetic profile. As shown by evidence from clinical trials, intravenous pegylated liposomal doxorubicin is a useful option in the treatment of various malignancies, including metastatic breast cancer, ovarian cancer, multiple myeloma, and AIDS-related Kaposi sarcoma. It has a favourable safety profile relative to conventional doxorubicin and other available chemotherapy agents.
This paper references
10.1093/annonc/mdr519
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.
D. Rayson (2012)
10.1200/JCO.2004.08.157
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alan M. Keller (2004)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxanerefractory advanced breast cancer
Am Keller (2004)
10.1093/ANNONC/MDL079
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
J. Sehouli (2006)
10.1200/JCO.2007.13.6606
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
G. Ferrandina (2008)
10.2165/11207510-000000000-00000
Pegylated Liposomal Doxorubicin
S. Duggan (2012)
Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma
St Duggan (2011)
10.1200/JCO.2006.09.6735
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
D. Mutch (2007)
10.1200/JCO.2009.25.7519
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
É. Pujade-Lauraine (2010)
10.1186/1471-2407-11-373
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
10.1159/000312644
High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies
J. Kesterson (2010)
10.1016/j.ejca.2012.04.001
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
B. Monk (2012)
10.1002/cncr.25362
Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma
Mary Cianfrocca (2010)
10.1200/JCO.2010.28.15_SUPPL.1022
A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study.
E. Jäger (2010)
10.1200/JCO.2006.10.5460
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
R. Orlowski (2007)
10.1007/s00280-008-0909-1
Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study
J. Sehouli (2008)
10.1200/JCO.2009.25.4037
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
B. Monk (2010)
10.1016/S1359-6349(08)70740-7
Interim safety analysis of a randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first line chemotherapy for metastatic breast cancer (MBC) – The PELICAN study
S. Al-Batran (2008)
10.1097/01.AIDS.0000131385.60974.B9
Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma
L. Martín-Carbonero (2004)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1111/j.1525-1438.2007.00992.x
Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer
Y. Yıldırım (2007)
10.1007/s10549-010-0860-9
Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
E. Alba (2010)
Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies doxorubicin for first-line treatment of metastatic breast cancer
Ann Oncol
(2004)
10.1200/JCO.2001.19.14.3312
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A. Gordon (2001)



This paper is referenced by
10.23880/vij-16000116
Improvement of Cancer Therapy by Nanotechnology
C. Mohanty (2017)
10.3109/02656736.2015.1057622
Synthesis and characterisation of ultrasound imageable heat-sensitive liposomes for HIFU therapy
D. Maples (2015)
10.3109/10717544.2015.1069421
Silicon-containing nanocarriers for targeted drug delivery: synthesis, physicochemical properties and acute toxicity
D. Sonin (2016)
The preclinical development of novel treatment options for advanced prostate cancer
Jan Kroon (2016)
10.1177/0300891619839308
Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis
D. Lorusso (2019)
10.1016/J.UROLS.2016.08.001
Comparison of therapeutic efficacy of lipo-doxorubicin and doxorubicin in treating bladder cancer
D. Yu (2017)
10.2147/DDDT.S140638
Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
J. Gong (2018)
10.1002/pros.22963
Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo
Jan Kroon (2015)
10.2147/IJN.S57946
Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells
Shao-ling Wu (2014)
10.1007/s12185-015-1773-5
Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
S. Kusumoto (2015)
10.1080/15384047.2015.1056416
Milk derived colloid as a novel drug delivery carrier for breast cancer
M. Hayashi (2015)
10.1002/cam4.491
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients
T. Golan (2015)
10.1016/j.clinre.2019.02.015
Cavitation-induced release of liposomal chemotherapy in orthotopic murine pancreatic cancer models: A feasibility study.
M. Camus (2019)
10.3389/fonc.2018.00681
Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems
Jo-Fan Chang (2019)
10.1007/978-3-030-01775-0_8
Delivery of Cancer Nanotherapeutics
Bomy Lee Chung (2019)
10.1038/nrneph.2016.156
Nanomedicines for renal disease: current status and future applications
Nazila Kamaly (2016)
10.1021/acs.chemrev.5b00116
Clinical Translation of Nanomedicine.
Y. Min (2015)
10.2217/fca.15.10
Malignant cardiac tumors: diagnosis and treatment.
C. Lestuzzi (2015)
10.1111/vco.12342
Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals.
B. Børresen (2018)
10.1002/btm2.10166
Hyaluronic acid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Daniel C Pan (2020)
Semantic Scholar Logo Some data provided by SemanticScholar